SPA
VTYX

Sherbrooke Park Advisers’s Ventyx Biosciences VTYX Stock Holding History

Sherbrooke Park Advisers’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-75,890
Closed -$175K – 1297
2024
Q2 		$175K Buy
+75,890
New +$315K 0.03% 785

Other funds holding VTYX

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sherbrooke Park Advisers's VTYX Position: Q3 2024 in Review

Sherbrooke Park Advisers sold out of Ventyx Biosciences (VTYX) in Q3 2024, closing a stake of 75,890 shares — an estimated $175K sold.

Sherbrooke Park Advisers first reported a position in VTYX in Q2 2024 and held it in 1 quarter. The position peaked at $175K in Q2 2024. 118 funds tracked by Wall St. Rank hold VTYX as of Q3 2024.

  • Sherbrooke Park Advisers reported no remaining Ventyx Biosciences position as of Q3 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 75,890 Ventyx Biosciences shares in Q3 2024, an estimated $175K.
  • Sherbrooke Park Advisers first reported a position in Ventyx Biosciences in Q2 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Ventyx Biosciences position peaked at $175K in Q2 2024.
  • 118 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q3 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2024, filed 14 Nov 2024.